Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

The Polynovo (PNV) Share Price Just Closed At A Record High

Polynovo Ltd (ASX: PNV) shares have continued its amazing run, finishing the day up 12% and taking 2019 gains to well over 400%. Is it too late to join the party?

About Polynovo

PolyNovo is an Australian medical device company that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats such as film, fibre, foam, and coatings.

Investors have been clamouring to get their hands on shares in the medical device company and the share price has been on a fast ride upwards as a result.

The fact that PolyNovo was added to the ASX200 late last month will have created even more demand for its shares. Being outside of the ASX 200 means many fund managers would have been unable to buy shares in the company prior due to their mandate not allowing the purchase of investments that sit outside the 200 largest stocks.

Is The Current Share Price Justified?

If you ask me, the PolyNovo share price certainly can’t be justified based on conventional metrics or any historical measure of company performance. PolyNovo is yet to earn a profit and in fact reported a loss of $3.19 million last financial year.

But clearly that’s not what shares in the company are being priced off.

I think today’s share price, which values the company at $1.68 billion, is a bit rich given that revenue was just $13.9 million in FY19. Roughly speaking, this equates to a revenue multiple of 120x.

[ls_content_block id=”14946″ para=”paragraphs”]

At the time of publishing, Luke has no financial interest in any companies mentioned.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report — or get it emailed to you — for FREE by CLICKING HERE NOW or the button below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content